{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:59Z","timestamp":1792783319988,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fundamental research program funding of Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine","award":["JYZZ247"],"award-info":[{"award-number":["JYZZ247"]}],"id":[{"id":"https:\/\/ror.org\/0220qvk04","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02301-1","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:47:50Z","timestamp":1791802070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of SUVmax and never-smoker\/never- or minimally-drinker history with PD-L1 expression in resected oral squamous cell carcinoma: a nodal-status-stratified analysis"],"prefix":"10.1007","author":[{"given":"Yuhua","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2371-9579","authenticated-orcid":false,"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"3","key":"2301_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"10212","key":"2301_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(19)32591-7.","journal-title":"Lancet"},{"issue":"8","key":"2301_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561\u201384. https:\/\/doi.org\/10.1038\/nrd4591.","journal-title":"Nat Rev Drug Discov"},{"key":"2301_CR4","doi-asserted-by":"publisher","first-page":"115395","DOI":"10.1016\/j.ejca.2025.115395","volume":"221","author":"M Tahara","year":"2025","unstructured":"Tahara M, Greil R, Rischin D, Harrington KJ, Burtness B, de Castro G, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. Eur J Cancer. 2025;221:115395. https:\/\/doi.org\/10.1016\/j.ejca.2025.115395.","journal-title":"Eur J Cancer"},{"issue":"19","key":"2301_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375(19):1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"issue":"10167","key":"2301_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/s0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156\u201367. https:\/\/doi.org\/10.1016\/s0140-6736(18)31999-8.","journal-title":"Lancet"},{"key":"2301_CR7","doi-asserted-by":"publisher","first-page":"153605","DOI":"10.1016\/j.prp.2021.153605","volume":"226","author":"G Paolino","year":"2021","unstructured":"Paolino G, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, et al. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. Pathol Res Pract. 2021;226:153605. https:\/\/doi.org\/10.1016\/j.prp.2021.153605.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"2301_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/1055-9965.epi-18-0779","volume":"28","author":"JC de Vicente","year":"2019","unstructured":"de Vicente JC, Rodr\u00edguez-Santamarta T, Rodrigo JP, Blanco-Lorenzo V, Allonca E, Garc\u00eda-Pedrero JM. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. 2019;28(3):546\u201354. https:\/\/doi.org\/10.1158\/1055-9965.epi-18-0779.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2301_CR9","doi-asserted-by":"publisher","first-page":"106183","DOI":"10.1016\/j.oraloncology.2022.106183","volume":"135","author":"BJ Park","year":"2022","unstructured":"Park BJ, Mattox AK, Clayburgh D, Patel M, Bell RB, Yueh B, et al. Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck. Oral Oncol. 2022;135:106183. https:\/\/doi.org\/10.1016\/j.oraloncology.2022.106183.","journal-title":"Oral Oncol"},{"key":"2301_CR10","doi-asserted-by":"publisher","first-page":"106869","DOI":"10.1016\/j.oraloncology.2024.106869","volume":"154","author":"S Beyaert","year":"2024","unstructured":"Beyaert S, Borys A, Baldin P, Dahou H, Magremanne M, Mahy P, et al. Study of the PD-L1 expression, T-cells density and immunoscore in paired baseline tumor biopsies and surgical specimens in squamous cell carcinoma of the oral cavity. Oral Oncol. 2024;154:106869. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106869.","journal-title":"Oral Oncol"},{"key":"2301_CR11","doi-asserted-by":"publisher","unstructured":"Liu N, Yan M, Tao Q, Wu J, Chen J, Chen X, et al. Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis. J Immunother Cancer. 2023;11(9). https:\/\/doi.org\/10.1136\/jitc-2023-007146.","DOI":"10.1136\/jitc-2023-007146"},{"issue":"1","key":"2301_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41419-025-07482-7","volume":"16","author":"CH Ding","year":"2025","unstructured":"Ding CH, Yan FZ, Xu BN, Qian H, Hong XL, Liu SQ, et al. PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma. Cell Death Dis. 2025;16(1):158. https:\/\/doi.org\/10.1038\/s41419-025-07482-7.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2301_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41416-023-02297-9","volume":"129","author":"J Li","year":"2023","unstructured":"Li J, Chen R, Chen Y, Xia Q, Zhou X, Xia Q, et al. Relationship between the expression of PD-L1 and (18)F-FDG uptake in pancreatic ductal adenocarcinoma. Br J Cancer. 2023;129(3):541\u201350. https:\/\/doi.org\/10.1038\/s41416-023-02297-9.","journal-title":"Br J Cancer"},{"issue":"5","key":"2301_CR14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00259-019-04500-7","volume":"47","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, et al. New insight on the correlation of metabolic status on (18)F-FDG PET\/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47(5):1127\u201336. https:\/\/doi.org\/10.1007\/s00259-019-04500-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"24","key":"2301_CR15","doi-asserted-by":"publisher","first-page":"12270","DOI":"10.18632\/aging.102567","volume":"11","author":"R Chen","year":"2019","unstructured":"Chen R, Chen Y, Huang G, Liu J. Relationship between PD-L1 expression and (18)F-FDG uptake in gastric cancer. Aging. 2019;11(24):12270\u20137. https:\/\/doi.org\/10.18632\/aging.102567.","journal-title":"Aging"},{"issue":"4","key":"2301_CR16","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s00259-018-4208-8","volume":"46","author":"R Chen","year":"2019","unstructured":"Chen R, Zhou X, Liu J, Huang G. Relationship between the expression of PD-1\/PD-L1 and (18)F-FDG uptake in bladder cancer. Eur J Nucl Med Mol Imaging. 2019;46(4):848\u201354. https:\/\/doi.org\/10.1007\/s00259-018-4208-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2301_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12149-020-01571-7","volume":"35","author":"YJ Choi","year":"2021","unstructured":"Choi YJ, Jo K, Hwang SH, Jeong Y, Lee JY, Kim S, et al. Association between PD-L1 expression and (18)F-FDG uptake in ovarian cancer. Ann Nucl Med. 2021;35(4):415\u201320. https:\/\/doi.org\/10.1007\/s12149-020-01571-7.","journal-title":"Ann Nucl Med"},{"issue":"11","key":"2301_CR18","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41416-020-0820-z","volume":"122","author":"M Togo","year":"2020","unstructured":"Togo M, Yokobori T, Shimizu K, Handa T, Kaira K, Sano T, et al. Diagnostic value of (18)F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8(+)tumour-infiltrating lymphocytes in oral squamous cell carcinoma. Br J Cancer. 2020;122(11):1686\u201394. https:\/\/doi.org\/10.1038\/s41416-020-0820-z.","journal-title":"Br J Cancer"},{"issue":"6","key":"2301_CR19","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.21873\/anticanres.13437","volume":"39","author":"H Takahashi","year":"2019","unstructured":"Takahashi H, Sakakura K, Arisaka Y, Tokue A, Kaira K, Tada H, et al. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma. Anticancer Res. 2019;39(6):3039\u201346. https:\/\/doi.org\/10.21873\/anticanres.13437.","journal-title":"Anticancer Res"},{"issue":"3","key":"2301_CR20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/hed.27981","volume":"47","author":"M Fiedler","year":"2025","unstructured":"Fiedler M, Off A, G\u00e4rtner A, Brockhoff G, Eichberger J, Gottsauner M, et al. Increased PD-1\/PD-L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never-Smokers and Never-Drinkers. Head Neck. 2025;47(3):822\u201331. https:\/\/doi.org\/10.1002\/hed.27981.","journal-title":"Head Neck"},{"key":"2301_CR21","doi-asserted-by":"publisher","unstructured":"Fiedler M, Off A, Eichberger J, Spoerl S, Schuderer JG, Taxis J, et al. OSCC in Never-Smokers and Never-Drinkers Is Associated with Increased Expression of Tumor-Infiltrating Lymphocytes and Better Survival. Cancers. 2023;15(10). https:\/\/doi.org\/10.3390\/cancers15102688.","DOI":"10.3390\/cancers15102688"},{"issue":"3","key":"2301_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/odi.15096","volume":"31","author":"Y Li","year":"2025","unstructured":"Li Y, Ren W, Li S, Zheng J, Gu H, Gao L, et al. The clinicopathological significance and prognostic value of PD-L1 in oral squamous cell carcinoma. Oral Dis. 2025;31(3):815\u201325. https:\/\/doi.org\/10.1111\/odi.15096.","journal-title":"Oral Dis"},{"issue":"3","key":"2301_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.15252\/embj.201695204","volume":"36","author":"GL Semenza","year":"2017","unstructured":"Semenza GL. Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. EMBO J. 2017;36(3):252\u20139. https:\/\/doi.org\/10.15252\/embj.201695204.","journal-title":"EMBO J"},{"issue":"5","key":"2301_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390. https:\/\/doi.org\/10.1084\/jem.20131916.","journal-title":"J Exp Med"},{"issue":"8","key":"2301_CR25","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1093\/annonc\/mdx210","volume":"28","author":"JP Foy","year":"2017","unstructured":"Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, et al. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1\/PD-L1 blockade. Ann Oncol. 2017;28(8):1934\u201341. https:\/\/doi.org\/10.1093\/annonc\/mdx210.","journal-title":"Ann Oncol"},{"issue":"3","key":"2301_CR26","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.7150\/ijbs.104079","volume":"21","author":"Q Liu","year":"2025","unstructured":"Liu Q, Liu Z, Zhang X, Zeng A, Song L. Revisiting of Cancer Immunotherapy: Insight from the Dialogue between Glycolysis and PD-1\/PD-L1 Axis in the Tumor Microenvironment. Int J Biol Sci. 2025;21(3):1202\u201321. https:\/\/doi.org\/10.7150\/ijbs.104079.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"2301_CR27","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1007\/s00330-024-10651-5","volume":"34","author":"DJ Hughes","year":"2024","unstructured":"Hughes DJ, Josephides E, O\u2019Shea R, Manickavasagar T, Horst C, Hunter S, et al. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([(18)F]FDG) positron emission tomography\/computed tomography (PET\/CT) metabolic parameters in resectable non-small cell lung cancer. Eur Radiol. 2024;34(9):5889\u2013902. https:\/\/doi.org\/10.1007\/s00330-024-10651-5.","journal-title":"Eur Radiol"},{"issue":"10","key":"2301_CR28","doi-asserted-by":"publisher","first-page":"8511","DOI":"10.21037\/jtd-2025-1118","volume":"17","author":"H Iwai","year":"2025","unstructured":"Iwai H, Yoshimura R, Tomoyasu M, Shigeeda W, Kaneko Y, Kanno H, et al. High PD-L1 expression correlates with lymph node metastasis in patients who have undergone radical surgery for primary pulmonary adenocarcinoma. J Thorac Dis. 2025;17(10):8511\u201321. https:\/\/doi.org\/10.21037\/jtd-2025-1118.","journal-title":"J Thorac Dis"},{"key":"2301_CR29","doi-asserted-by":"publisher","first-page":"1012561","DOI":"10.3389\/fonc.2022.1012561","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Huo Y, Ma C, Lv Z. Relationship between standardized uptake value on 18F-FDG PET and PD-L1 expression in clear cell renal cell carcinoma. Front Oncol. 2022;12:1012561. https:\/\/doi.org\/10.3389\/fonc.2022.1012561.","journal-title":"Front Oncol"},{"issue":"2","key":"2301_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-025-07453-2","volume":"53","author":"FJ Kiss","year":"2026","unstructured":"Kiss FJ, J\u00e1r\u00f3 AI, M\u00e1th\u00e9 D, Benedek C, Madaras V, Manno-Kov\u00e1cs A, et al. Predicting PD-L1 expression status in NSCLC using radiomic analysis of 18 F-FDG-PET\/CT images. Eur J Nucl Med Mol Imaging. 2026;53(2):800\u201311. https:\/\/doi.org\/10.1007\/s00259-025-07453-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2301_CR31","doi-asserted-by":"publisher","first-page":"e241962","DOI":"10.1148\/radiol.241962","volume":"318","author":"R O\u2019Shea","year":"2026","unstructured":"O\u2019Shea R, Horst C, Manickavasagar T, Josephides E, Hunter S, Taniere P, et al. Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer. Radiology. 2026;318(3):e241962. https:\/\/doi.org\/10.1148\/radiol.241962.","journal-title":"Radiology"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02301-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02301-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02301-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:32:21Z","timestamp":1791847941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02301-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":31,"alternative-id":["2301"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02301-1","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}